Search Result
Results for "
hyperuricemia
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-147300
-
-
-
- HY-139585
-
|
LC350189
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Tigulixostat (LC350189) is an orally active, non-purine selective xanthine oxidase inhibitor. Tigulixostat lowers the production of uric acid. Tigulixostat can be used for gout and hyperuricemia study .
|
-
-
- HY-19164
-
-
-
- HY-160265
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia .
|
-
-
- HY-144303
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research .
|
-
-
- HY-161523
-
|
|
Xanthine Oxidase
URAT1
|
Metabolic Disease
|
|
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .
|
-
-
- HY-151975
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia .
|
-
-
- HY-151973
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia .
|
-
-
- HY-N9959
-
|
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
Isoengeletin is a flavonoid that can be isolated from the roots of Smilax bockii warb. Isoengeletin can be used as an active compound for the research of psoriasis, hyperuricemia and gout .
|
-
-
- HY-W047156
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Allantoxanamide is a uricase inhibitor. Allantoxanamide-induced rats serve as animal models for studying purine biosynthesis, drug-induced hyperuricemia and hyperuricosuria, and related nephropathy .
|
-
-
- HY-14268
-
-
-
- HY-14268A
-
-
-
- HY-161514
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) (IC50=0.13 μM). Xanthine oxidase-IN-15 inhibits XO catalysis by forming a stable interaction with the active site of XO. Xanthine oxidase-IN-15 is mainly used in the study of hyperuricemia and gout .
|
-
-
- HY-162882
-
|
|
Xanthine Oxidase
Reactive Oxygen Species
|
Metabolic Disease
|
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .
|
-
-
- HY-14268R
-
|
|
Xanthine Oxidase
|
Cardiovascular Disease
Metabolic Disease
|
|
Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .
|
-
-
- HY-158056
-
|
|
GLUT
URAT1
|
Metabolic Disease
|
|
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .
|
-
-
- HY-146273
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .
|
-
-
- HY-P2921B
-
|
Uox, Arthrobacter globiformis
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-P2921A
-
|
Uox, Bacillus fastidious
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-P2921C
-
|
Uox (Recombinant)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .
|
-
-
- HY-N8309
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
|
-
-
- HY-14874
-
|
FYX-051
|
Xanthine Oxidase
Cytochrome P450
|
Metabolic Disease
|
|
Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .
|
-
-
- HY-111345
-
|
UR-1102; URC-102
|
OAT
URAT1
|
Metabolic Disease
Inflammation/Immunology
|
|
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .
|
-
-
- HY-111345A
-
|
UR-1102 hydrochloride; URC-102 hydrochloride
|
OAT
URAT1
|
Metabolic Disease
Inflammation/Immunology
|
|
Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research .
|
-
-
- HY-14874R
-
|
|
Xanthine Oxidase
Cytochrome P450
|
Metabolic Disease
|
|
Topiroxostat (Standard) is the analytical standard of Topiroxostat. This product is intended for research and analytical applications. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .
|
-
-
- HY-N8309R
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
|
-
-
- HY-153972
-
|
|
URAT1
Xanthine Oxidase
|
Metabolic Disease
Inflammation/Immunology
|
|
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .
|
-
-
- HY-B0219
-
Allopurinol
Maximum Cited Publications
8 Publications Verification
|
Xanthine Oxidase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
|
-
-
- HY-B0219A
-
|
|
Xanthine Oxidase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
|
-
-
- HY-162910
-
|
|
Xanthine Oxidase
HDAC
Autophagy
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition .
|
-
-
- HY-B0219R
-
|
|
Xanthine Oxidase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .
|
-
-
- HY-N8063
-
|
|
Endogenous Metabolite
|
Others
|
|
γ-Glutamylornithine is the urine excreta of patients with HHH syndrome (hyperuricemia, hyperaminemia, and hypercitrullinuria) and rotary atrophy associated with hyperuricemia. Increased levels of endogenous ornithine increase levels of γ-Glutamylornithine in the urine .
|
-
-
- HY-143906
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC50 values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .
|
-
-
- HY-101439
-
|
|
URAT1
|
Others
|
|
JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.
|
-
-
- HY-W052011
-
|
HR011303; SHR4640
|
URAT1
|
Metabolic Disease
|
|
Ruzinurad (HR011303) is a highly selective URATl inhibitor (WO2020088641, compound I). Ruzinurad can be used in the study of hyperuricemia .
|
-
-
- HY-156624
-
|
|
URAT1
|
Metabolic Disease
|
|
Lingdolinurad is urate transporter inhibitor, targeting to hURAT1.Lingdolinurad can be used for research in hyperuricemia in vitro and in vivo .
|
-
-
- HY-157306
-
|
|
URAT1
|
Metabolic Disease
|
|
HC-1310 URAT1 Inhibitor (Compound 83) is a potent URAT1 inhibitor and can be used for research on hyperuricemia and gout .
|
-
-
- HY-153706
-
-
-
- HY-153968
-
|
|
Xanthine Oxidase
URAT1
|
Metabolic Disease
|
|
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research .
|
-
-
- HY-108844
-
|
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Rasburicase is a recombinant urate oxidase and a hyperuricemia inhibitor. Rasburicase converts uric acid into allantoin, making it easier to be cleared by the kidneys and improving the elevated level of uric acid in the blood .
|
-
-
- HY-14669
-
|
Y-700; Piraxostat
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved .
|
-
-
- HY-113048
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .
|
-
-
- HY-113048A
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .
|
-
-
- HY-162961
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-16 is potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 102 nM. Xanthine oxidase-IN-16 shows significant efficacy in hyperuricemia rats .
|
-
-
- HY-N8761
-
|
|
NO Synthase
|
Metabolic Disease
|
|
Kihadanin A (compound 3) is a limonoid NOS3 inhibitor that can be isolated from the methanol extract of Dictamnus dasycarpus root bark. Kihadanin A is useful in the study of hyperuricemia (HUA) [3].
|
-
-
- HY-B1135
-
-
-
- HY-114309
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC50 of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .
|
-
-
- HY-162829
-
|
|
URAT1
GLUT
|
Metabolic Disease
|
|
hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics .
|
-
-
- HY-B0219S
-
-
-
- HY-P2813
-
|
|
Thrombin
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
|
-
- HY-151974
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor. Xanthine oxidoreductase-IN-4 has inhibitory activity against XOR with an IC50 value of 29.3 nM. Xanthine oxidoreductase-IN-4 can be used for the research of hyperuricemia .
|
-
- HY-146560
-
-
- HY-119453
-
-
- HY-B1135R
-
-
- HY-144305
-
|
|
URAT1
GLUT
|
Infection
|
|
KPH2f is a safe, orally active, and effective dual URAT1/GLUT9 inhibitor with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC50=32.14 and 26.74 μM) .
|
-
- HY-N10433
-
|
Icarisids E
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 31.81 μM .
|
-
- HY-14874S
-
|
FYX-051-d4
|
Isotope-Labeled Compounds
Xanthine Oxidase
Cytochrome P450
|
Metabolic Disease
|
|
Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment[1][2].
|
-
- HY-N9324
-
|
|
Xanthine Oxidase
|
Inflammation/Immunology
|
|
Ilexoside O is a triterpene saponin isolated from the roots of Ilex pubescens. Ilexoside O exhibits weak xanthine oxidase (XOD) inhibitory activity (IC50=53.05 μM) .
|
-
- HY-116433
-
-
- HY-151173
-
-
- HY-163431
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 10 (Compound 23a) is a URAT1 inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 .
|
-
- HY-116433R
-
|
|
Parasite
Xanthine Oxidase
|
Infection
Metabolic Disease
|
|
Nequinate (Standard) is the analytical standard of Nequinate. This product is intended for research and analytical applications. Nequinate, a quinoline compound, is an anticoccidial agent against cecal coccidiosis (Eimeria tenella) infections . Nequinate inhibits xanthine oxidoreductase (XOD) activity .
|
-
- HY-144456
-
|
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2813
-
|
|
Thrombin
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0219S
-
|
|
|
Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect[1][2].
|
-
-
- HY-14874S
-
|
|
|
Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
